Rhumbline Advisers raised its holdings in SAGE Therapeutics Inc (NASDAQ:SAGE) by 3.8% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 48,684 shares of the biopharmaceutical company’s stock after acquiring an additional 1,777 shares during the quarter. Rhumbline Advisers owned 0.10% of SAGE Therapeutics worth $7,743,000 as of its most recent filing with the SEC.
Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc increased its position in SAGE Therapeutics by 6.9% in the 3rd quarter. Vanguard Group Inc now owns 4,085,812 shares of the biopharmaceutical company’s stock worth $577,121,000 after purchasing an additional 262,990 shares during the last quarter. Suffolk Capital Management LLC lifted its position in shares of SAGE Therapeutics by 20.3% in the 4th quarter. Suffolk Capital Management LLC now owns 111,908 shares of the biopharmaceutical company’s stock worth $10,720,000 after acquiring an additional 18,908 shares during the period. JGP Global Gestao de Recursos Ltda. bought a new stake in shares of SAGE Therapeutics in the 4th quarter worth approximately $477,000. Strs Ohio lifted its position in shares of SAGE Therapeutics by 61.5% in the 4th quarter. Strs Ohio now owns 230,000 shares of the biopharmaceutical company’s stock worth $22,031,000 after acquiring an additional 87,583 shares during the period. Finally, Fiduciary Trust Co. lifted its position in shares of SAGE Therapeutics by 8.5% in the 4th quarter. Fiduciary Trust Co. now owns 25,400 shares of the biopharmaceutical company’s stock worth $2,433,000 after acquiring an additional 2,000 shares during the period.
A number of analysts have commented on SAGE shares. Guggenheim began coverage on SAGE Therapeutics in a research report on Friday, February 22nd. They issued a “buy” rating and a $205.00 price objective for the company. ValuEngine cut SAGE Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 18th. Jefferies Financial Group began coverage on SAGE Therapeutics in a report on Thursday, April 25th. They set a “buy” rating and a $195.00 price target for the company. Canaccord Genuity set a $220.00 price target on SAGE Therapeutics and gave the company a “buy” rating in a report on Monday, April 8th. Finally, Oppenheimer set a $170.00 price target on SAGE Therapeutics and gave the company a “buy” rating in a report on Sunday, May 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and fifteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $202.15.
NASDAQ SAGE traded down $1.58 on Friday, hitting $174.26. 197,266 shares of the company’s stock were exchanged, compared to its average volume of 559,746. The stock has a market capitalization of $8.63 billion, a PE ratio of -21.57 and a beta of 2.67. The company has a debt-to-equity ratio of 0.03, a current ratio of 20.06 and a quick ratio of 20.06. SAGE Therapeutics Inc has a 52 week low of $79.88 and a 52 week high of $178.16.
SAGE Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($3.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.17) by ($0.20). The firm had revenue of $0.47 million for the quarter. During the same quarter in the prior year, the firm earned ($1.68) earnings per share. As a group, sell-side analysts expect that SAGE Therapeutics Inc will post -13.19 earnings per share for the current year.
In other news, insider Michael Cloonan sold 25,000 shares of the stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $175.00, for a total transaction of $4,375,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Anne Marie Cook sold 15,000 shares of the stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $166.14, for a total transaction of $2,492,100.00. Following the transaction, the senior vice president now directly owns 15,000 shares in the company, valued at approximately $2,492,100. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 291,121 shares of company stock valued at $49,791,439. Company insiders own 4.60% of the company’s stock.
SAGE Therapeutics Profile
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).
Further Reading: Key terms to understand channel trading
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.